Stock2Me Podcast featuring Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (TRYPF)
Stock2Me’s latest podcast features Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing treatments, primarily psychedelics like psilocybin, for diseases with unmet medical needs.
Throughout the interview, McKee discussed the company’s prospective patients and targeted ailments, the need for innovation in the psychedelics space and Tryp’s planned human clinical trials later this year.
“We’re here fundamentally to help patients. We’re also very interested in bringing new therapies to these patients. All these indications that we’re working in – specifically fibromyalgia, phantom limb syndrome and complex regional pain syndrome, and potentially others such as tinnitus, cluster headaches, TMJ and others – all these subcategories of chronic pain are areas where there is significant unmet medical need,” McKee said. “In other words, situations where patients aren’t properly served. We know that new chemistries and new solutions need to be brought to the table. There needs to be a broader set of tools that physicians can use to treat these patients.”
It is Free
Copyright © 2006-2022 Podbean.com